SG11201911757WA - Novel multivalent polysaccharide - protein conjugate vaccine composition and formulation thereof - Google Patents
Novel multivalent polysaccharide - protein conjugate vaccine composition and formulation thereofInfo
- Publication number
- SG11201911757WA SG11201911757WA SG11201911757WA SG11201911757WA SG11201911757WA SG 11201911757W A SG11201911757W A SG 11201911757WA SG 11201911757W A SG11201911757W A SG 11201911757WA SG 11201911757W A SG11201911757W A SG 11201911757WA SG 11201911757W A SG11201911757W A SG 11201911757WA
- Authority
- SG
- Singapore
- Prior art keywords
- formulation
- vaccine composition
- protein conjugate
- conjugate vaccine
- novel multivalent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Toxicology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201711022396 | 2017-06-27 | ||
PCT/IN2018/050253 WO2019003238A1 (en) | 2017-06-27 | 2018-04-26 | NOVEL MULTIVALENT VACCINE COMPOSITION CONTAINING POLYSACCHARIDE - PROTEIN CONJUGATES AND FORMULATION THEREOF |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201911757WA true SG11201911757WA (en) | 2020-01-30 |
Family
ID=64741206
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201911757WA SG11201911757WA (en) | 2017-06-27 | 2018-04-26 | Novel multivalent polysaccharide - protein conjugate vaccine composition and formulation thereof |
Country Status (10)
Country | Link |
---|---|
US (1) | US20200147198A1 (ja) |
EP (1) | EP3645045A4 (ja) |
JP (1) | JP2020525495A (ja) |
KR (1) | KR20200018784A (ja) |
CN (1) | CN110809477A (ja) |
BR (1) | BR112019027182A2 (ja) |
RU (1) | RU2019142846A (ja) |
SG (1) | SG11201911757WA (ja) |
WO (1) | WO2019003238A1 (ja) |
ZA (1) | ZA201908271B (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20200353064A1 (en) * | 2018-01-29 | 2020-11-12 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | Novel meningococcal vaccine composition and process thereof |
WO2019198096A1 (en) * | 2018-04-11 | 2019-10-17 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | Tetravalent meningococcal vaccine composition and process to prepare thereof |
GB202208089D0 (en) * | 2022-06-01 | 2022-07-13 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
CN118078981A (zh) * | 2024-04-26 | 2024-05-28 | 成都康华生物制品股份有限公司 | 一种基于双蛋白载体的五价脑膜炎球菌多糖结合疫苗的制备方法及其产品 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0500787D0 (en) * | 2005-01-14 | 2005-02-23 | Chiron Srl | Integration of meningococcal conjugate vaccination |
GB0703369D0 (en) * | 2007-02-21 | 2007-03-28 | Health Prot Agency | Compositions Comprising Capsular Polysaccharides and Their Use as Vaccines |
HUE040914T4 (hu) * | 2012-01-30 | 2019-05-28 | Serum Institute Of India Pvt Ltd | Immunogén készítmény |
WO2013174832A1 (en) * | 2012-05-22 | 2013-11-28 | Novartis Ag | Meningococcus serogroup x conjugate |
JP2019508468A (ja) * | 2016-03-15 | 2019-03-28 | エムエスディー ウェルカム トラスト ヒルマン ラボラトリーズ プライベート リミテッドMsd Wellcome Trust Hilleman Laboratories Pvt.Ltd. | 新規の多糖体−タンパク質コンジュゲート及びそれを得る方法 |
US20200353064A1 (en) * | 2018-01-29 | 2020-11-12 | Msd Wellcome Trust Hilleman Laboratories Pvt. Ltd. | Novel meningococcal vaccine composition and process thereof |
-
2018
- 2018-04-26 BR BR112019027182-1A patent/BR112019027182A2/pt active Search and Examination
- 2018-04-26 US US16/625,246 patent/US20200147198A1/en not_active Abandoned
- 2018-04-26 CN CN201880042052.1A patent/CN110809477A/zh active Pending
- 2018-04-26 KR KR1020197037324A patent/KR20200018784A/ko not_active Application Discontinuation
- 2018-04-26 WO PCT/IN2018/050253 patent/WO2019003238A1/en active Application Filing
- 2018-04-26 SG SG11201911757WA patent/SG11201911757WA/en unknown
- 2018-04-26 JP JP2019572359A patent/JP2020525495A/ja not_active Abandoned
- 2018-04-26 EP EP18825493.2A patent/EP3645045A4/en not_active Withdrawn
- 2018-04-26 RU RU2019142846A patent/RU2019142846A/ru not_active Application Discontinuation
-
2019
- 2019-12-11 ZA ZA2019/08271A patent/ZA201908271B/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA201908271B (en) | 2022-07-27 |
KR20200018784A (ko) | 2020-02-20 |
WO2019003238A1 (en) | 2019-01-03 |
EP3645045A4 (en) | 2021-03-31 |
CN110809477A (zh) | 2020-02-18 |
JP2020525495A (ja) | 2020-08-27 |
EP3645045A1 (en) | 2020-05-06 |
US20200147198A1 (en) | 2020-05-14 |
RU2019142846A3 (ja) | 2021-11-09 |
BR112019027182A2 (pt) | 2020-06-30 |
RU2019142846A (ru) | 2021-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL297575B1 (en) | Multivalent vaccines for lung spot that include polysaccharide-protein conjugates | |
ZA201901346B (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
IL276229B1 (en) | A multivalent pneumococcal protein-polysaccharide conjugate preparation | |
ZA202202600B (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
ZA201901345B (en) | Multivalent pneumococcal polysaccharide-protein conjugate composition | |
EP3668541A4 (en) | FORMULATIONS FOR PNEUMOCOCCAL CONJUGATE VACCINE | |
ZA201708325B (en) | Methods for improving the adsorption of polysaccharide-protein conjugates and multivalent vaccine formulation obtained thereof | |
EP3585803A4 (en) | PNEUMOCOCCIC CONJUGATE VACCINE FORMULATIONS | |
IL268168A (en) | Immunogenic preparations for use as a vaccine against pneumococcus | |
IL290182A (en) | Polyvalent pneumococcal polysaccharide-protein conjugated compounds and methods and use thereof | |
HUE051728T2 (hu) | Konjugált burokszaccharid antigéneket tartalmazó immunogén készítmények és alkalmazásaik | |
ZA201708713B (en) | Multivalent pneumococcal conjugate vaccine | |
SG11201911757WA (en) | Novel multivalent polysaccharide - protein conjugate vaccine composition and formulation thereof | |
IL308201A (en) | Multivalent vaccine compositions and uses thereof | |
IL284349A (en) | A polyvalent polysaccharide-protein conjugate vaccine of the show dot | |
ZA201901969B (en) | A composition of multivalent pneumococcal capsular polysaccharide-carrier protein conjugates and use thereof | |
IL264605A (en) | A multivalent vaccine | |
GB201721582D0 (en) | S aureus antigens and immunogenic compositions | |
EP3307311A4 (en) | MULTIVALENT ENTEROVIRUS VACCINE COMPOSITIONS AND USES THEREOF | |
ZA202103644B (en) | Multivalent glycoconjugates immunogenic compositions | |
GB201712096D0 (en) | Immunogenic conjugates and use thereof |